Ask AI

Capsule Summaries

Share

Program Content

Activities

  • INCA033989 in ET
    Phase I Trial of INCA033989, a First-in-Class Antibody Targeting Mutant Calreticulin: Safety and Efficacy in Essential Thrombocythemia
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with Smart Patients.

Supporters

Supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

BeOne Medicines

Genentech

Geron Corporation

Incyte

Johnson & Johnson

Lilly

Novartis Pharmaceuticals Corporation

Partners

Smart Patients

ProCE Banner